Key result
Dobutamine is far from ideal as a long-term safe strategy for heart failure, necessitating the development of new drugs for acute heart failure.
Key points are not available for this paper at this time.
Design
Editorial
Highlights the need for new therapeutic approaches for acute heart failure to replace or improve upon dobutamine.
The development of dobutamine, an infusible inotropic drug for heart failure, was first described in 1975. Although this sympathomimetic was designed to increase cardiac output, it is far from ideal as a longterm safe strategy. New drugs for acute heart failure are needed, and to develop new approaches will require diverse expertise and resources.
No takes yet. Share an insight, caveat, or question.
Elizabeth M. McNally (2013) studied this question. Dobutamine is far from ideal as a long-term safe strategy for heart failure, necessitating the development of new drugs for acute heart failure.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: